Proteome Sciences Share Discussion Threads

[goatherd] 08/12/2022 18:31

So what do we get, please?

[colinhy] 08/12/2022 15:47

ThermoFisher Scientific Webinar, Thursday, December 15, 2022, 4PM GMT

Pushing the limits of multiplexed single-cell proteomics

Single-cell proteomics has recently emerged as a promising new field capable of elucidating the vast cellular heterogeneity that defines biology, disease, and therapeutic response.

However, it is also extremely challenging, since accurate identification and quantification must be performed across entire proteomes from vanishingly small amounts of material analyzed over short, single-shot LC-MS runs. This necessitates extremes of performance from nano-flow LC and MS systems and their optimization for maximal sensitivity, speed, and depth.

This webcast will cover a roadmap for single-cell proteomics parameter optimization for human immune cell profiling using the tandem mass tag (TMT) multiplexed SCoPE-MS methodology on Thermo Scientific™ Vanquish™ Neo UHPLC System and Thermo Scientific™ Orbitrap Exploris™ 480 MS platforms. It will also describe recent advances in TMT complement ion quantification using on-the-fly phased spectrum decomposition method (SDM or phi-SDM) super-resolution signal processing via GPU-compute box architecture and complement ion data analysis within the Thermo Scientific™ ProteomeDiscover™ software framework.

These TMT complement ion approaches may help usher in a new era of highly accurate multiplexing in next-gen deep proteomics using wide-window or data-independent acquisition (DIA) methods.

You will learn:
The advantage of performing TMT-based single-cell proteomics
Latest MS advances to benefit single-cell proteomics
Single-cell proteomics MS parameter optimization for human immune cell profiling

[dominiccummings] 06/12/2022 20:31

No. You don't understand. The 'guesstimates led him to his opinion. They must have a life of their own!

[peverill] 06/12/2022 17:16

So yes,you changed them.

[monte1] 06/12/2022 14:47

You are truly beyond saving matey.

[goatherd] 06/12/2022 14:03

monte,

I never have changed any post of mine (except for minor edits, invariably in less than a day; and usually immediately after the initial post - when I have read it, and needed to clarify).

All the posts were clearly labelled "guesstimates" at original post; all the caveats were included in the original post.

Tom,

Actually the "guesstimates" were not ridiculous; though I think they were on the low side. I said why I was making them.

The reason was that I was unsure whether a diagnostics company (which Proteome was heading to be) could ever be as profitable as a treatments company. The guesstimates showed that they COULD be.

One of the main caveats was "that the tests work and can be sold". Unfortunately they didn't and so couldn't.

[peverill] 06/12/2022 12:43

And let's not forget the cheerleading of the GE £5 takeover.

[tom barnaby] 06/12/2022 10:50

I hardly think the 'guesstimates', ridiculous as they always were are the extent of the subject matter. Years upon years of just around the door promises that will make avatars richer than croesus, 'theories', supposed buy outs being rejected.

A list as long as your arm, if anyone cares to look back.

As monte1 states, not just 'here' either.

If the avatar was assessed in Timeform, he would have "The squiggle", no doubt about it.

[monte1] 06/12/2022 10:35

A good point goatherd - and very well made at that. Although tbf, the labels, warnings and caveats tend to be rewrites of history added when the original claims are proven to be utter tosh.

[goatherd] 06/12/2022 10:31

So, Tom and Monte, why do you think ANYONE makes an investment based on what appears in a "guesstimate"; especially when there are numerous caveats attached to each and every one?

[monte1] 06/12/2022 09:33

And not just ‘here’, he is a scoundrel, a rogue and a bounder AIM wide.

[tom barnaby] 06/12/2022 08:13

91820

The bloke may not be to blame for your terrible investment, but he most certainly is (at least) partly to blame for many and both he and you know it.

[peverill] 06/12/2022 06:05

People have licensed a few things from PRM over the years,as yet nothing has materialised from such licenses.A lot of money spent on wages/expenses,recruitment,all of which has left Shareholders out in the cold.Borrowing money from a major shareholder which they can't repay,despite directors receiving a nice wage every year.Haigh received £1m during his tenure,delivered SFA,Mariola,has delivered SFA 2 years in,who is next through the turnstile ???.

[jeffian] 05/12/2022 23:05

blue,

It's not "attacking" to call out statements put into the public domain which stretch credulity to the limit, it's challenging. goatherd has consistently called most things wrong and hides behind the device of 'timing', as if 20+ years of losses and failed promises can be wiped out by something that may, or may not, happen at an indiscernible point in the future. It is hard to reconcile persistent claims that his PRM holding is at breakeven or even in profit when a glimpse at the chart over the long term shows the pattern of starting in the top left hand corner and finishing currently at the very bottom of the right hand corner. As I have pointed out in the past, it would have been possible to make very handsome profits out of PRM if you had bought every trough and sold every peak, but that would require trading like a Spaniard and getting every trade right, neither of which featured in goatherd's posts over the period.

Now cast your eyes up to #91810 (I would do, but my eyeballs fell out with the shock). "I have back tested from 20001 for the UK and 2003 for USA, and they have shown a remarkable consistency, with an average annual return of around 50%." Does that say what I think it says?! So if goatherd had a portfolio, ex-'story' shares, of £100,000, he would now be sitting on around £2.2bn!

goatherd may not lie, but I'm afraid I don't believe a word he says.

[bluemango] 05/12/2022 22:58

Yawn. You might not like the reminder that both Randox and Galaxy have licensed stroke biomarkers from Proteome, but it happens to be the reality.

Whether or when either become fruition is anyone's guess.

[bluemango] 05/12/2022 19:48

Btw it is two potential stroke tests, not just the one.

Randox and Galaxy. Of which Randox is more likely to come first.

And please can people lay off continually attacking goatherd. We all know that cynicism is the default attitude here, but it gets very tedious when you all overplay it, just like the over-optimism was clearly equally extreme historically. It doesn't advance the debate/discussion one iota, it's just boring and, tbh, unkind.

[goatherd] 05/12/2022 19:42

I have heard through two, totally separate channels, that it will be "any day now".

I believe my sources are honest - I just hope their sources are knowledgeable - there is every reason why they should be.

I shall be very disappointed if it does not come in this year.

[peverill] 05/12/2022 19:28

Where is this stroke test???

[goatherd] 05/12/2022 19:21

monte,

Well, we will see. You think you will be right.

But, I am sure I will be.